source
- FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravisThe FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…